Lenalidomide for the Treatment of B-Cell Malignancies
作者： Asher A. Chanan-Khan , Bruce D. Cheson
关键词:
摘要: Lenalidomide is a novel anticancer agent that has made major impact in the treatment of patients with B-cell malignancies. A more potent analog thalidomide, lenalidomide was developed to enhance immunomodulatory properties improved safety profile. Its antitumor activity seems mediated through modulation both cytokine and cellular tumor cell microenvironment. Preclinical as well clinical observations demonstrate downregulates production various critical prosurvival cytokines microenvironment while concurrently promoting activation T- natural killer (NK) cell-mediated response. Early investigations noted its efficacy relapsed and/or refractory multiple myeloma patients. Subsequently, larger randomized studies confirmed benefit when added dexamethasone compared alone previously treated resulting recent approval by US Food Drug Administration. Consequently, role other malignancies been investigated, impressive results chronic lymphocytic leukemia non-Hodgkin's lymphoma. This review summarizes data from highlights management
elsevier.com
sci-hub.se 参考文章(80)
Thomas A, El Rouby S, Krajewski S, Reed Jc, Newcomb Ew, Potmesil M, Silber R, Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. ,vol. 12, pp. 1055- 1062 ,(1996)
Patrick B. Johnston, Neil E. Kay, Pathogenesis of Impaired Cellular Immune Function in CLL Humana Press, Totowa, NJ. pp. 109- 121 ,(2004) , 10.1007/978-1-59259-412-2_5
David M. Dorfman, Joachim L. Schultze, Aliakbar Shahsafaei, Sabine Michalak, John G. Gribben, Gordon J. Freeman, Geraldine S. Pinkus, Lee M. Nadler, In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation Blood. ,vol. 90, pp. 4297- 4306 ,(1997) , 10.1182/BLOOD.V90.11.4297
M. Wang, R. Knight, M. Dimopoulos, D. Siegel, S. V. Rajkumar, T. Facon, Z. Yu, J. Zeldis, M. Olesnyckyj, D. M. Weber, Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma Journal of Clinical Oncology. ,vol. 24, pp. 7522- 7522 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7522
Reed Jc, Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Seminars in Hematology. ,vol. 34, pp. 9- 19 ,(1997)
J. Blake Bartlett, Keith Dredge, Angus G. Dalgleish, The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer. ,vol. 4, pp. 314- 322 ,(2004) , 10.1038/NRC1323
Meletios A. Dimopoulos, Athanassios Zomas, Nora A. Viniou, Vassiliki Grigoraki, Eleni Galani, Charis Matsouka, Olga Economou, Nikolaos Anagnostopoulos, Panayiotis Panayiotidis, Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide Journal of Clinical Oncology. ,vol. 19, pp. 3596- 3601 ,(2001) , 10.1200/JCO.2001.19.16.3596
Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Ling-Hua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George Muller, Peter Schafer, David Stirling, Angus G. Dalgleish, J. Blake Bartlett, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research. ,vol. 69, pp. 56- 63 ,(2005) , 10.1016/J.MVR.2005.01.002
NE Kay, ND Bone, RC Tschumper, KH Howell, SM Geyer, GW Dewald, CA Hanson, DF Jelinek, B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules Leukemia. ,vol. 16, pp. 911- 919 ,(2002) , 10.1038/SJ.LEU.2402467
Morton Coleman, John Leonard, Larry Lyons, Karen Pekle, Kenneth Nahum, Roger Pearse, Ruben Niesvizky, Joseph Michaeli, BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & Lymphoma. ,vol. 43, pp. 1777- 1782 ,(2002) , 10.1080/1042819021000006303